Alharbi Oqab, Albaibi Sofian A, Almutairi Abdullah A, Alsaqabi Emad, Alharbi Meshal, Alharbi Bader S, Almansour Mohammad F, Al-Qahtani Zainah A
Neurology, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah, SAU.
Medicine, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah, SAU.
Cureus. 2024 Dec 19;16(12):e76016. doi: 10.7759/cureus.76016. eCollection 2024 Dec.
Essential tremor (ET) is one of the most prevalent nerve-related movement disorders, most commonly affecting the hands during voluntary movements or while maintaining posture. Unlike tremors in neurodegenerative conditions, ET is not observed at rest. Continued research is essential to optimize treatment strategies and address the unmet need for sustainable, patient-centered therapies that minimize side effects and enhance long-term quality of life (QoL) for individuals with ET. Five medical databases were searched for content relevant to this study's topic, utilizing the guidelines set forth by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). These databases searched include Web of Science, PubMed, Cochrane Library, ScienceDirect, and Google Scholar for publications between 2010 and 2024. The review analyzed studies including adult patients with ET, focusing on efficacy, safety, and QoL outcomes, with priority given to studies from the Middle East or Saudi Arabia. We included 10 studies that met our inclusion criteria for a full review. Based on the studies, pharmacological treatments such as alprazolam, primidone, propranolol, and CX-8998 were found to be efficient in the management of ET. Emerging medications, including CX-8998 and alprazolam, showed mixed results with significant adverse events. Surgical interventions like deep brain stimulation (DBS) demonstrated long-term motor control benefits, although functional declines occurred due to disease progression. Novel approaches like low-intensity focused ultrasound (LIFU), transcutaneous afferent patterned stimulation (TAPS), and incobotulinumtoxinA injections presented promising results with improved tremor control and minimal side effects. In conclusion, pharmacological treatments for ET provide symptomatic relief but are limited by side effects and reduced long-term efficacy, significantly impacting QoL. Surgical and novel therapeutic options offer enhanced motor control and durability of effects, though they are not universally applicable.
特发性震颤(ET)是最常见的神经相关运动障碍之一,最常影响手部的自主运动或维持姿势时的手部。与神经退行性疾病中的震颤不同,ET在静止时不会出现。持续的研究对于优化治疗策略以及满足对可持续的、以患者为中心的疗法的未满足需求至关重要,这些疗法可将副作用降至最低并提高ET患者的长期生活质量(QoL)。利用系统评价和Meta分析的首选报告项目(PRISMA)制定的指南,检索了五个医学数据库中与本研究主题相关的内容。检索的这些数据库包括科学网、PubMed、考克兰图书馆、ScienceDirect和谷歌学术,以查找2010年至2024年期间的出版物。该综述分析了包括成年ET患者的研究,重点关注疗效、安全性和生活质量结果,优先考虑来自中东或沙特阿拉伯的研究。我们纳入了10项符合全面综述纳入标准的研究。基于这些研究,发现诸如阿普唑仑、扑米酮、普萘洛尔和CX - 8998等药物治疗在ET的管理中是有效的。包括CX - 8998和阿普唑仑在内的新兴药物显示出好坏参半的结果,伴有显著的不良事件。像深部脑刺激(DBS)这样的手术干预显示出长期的运动控制益处,尽管由于疾病进展会出现功能下降。像低强度聚焦超声(LIFU)、经皮传入模式刺激(TAPS)和注射incobotulinumtoxinA等新方法呈现出有希望的结果,震颤控制得到改善且副作用最小。总之,ET的药物治疗可缓解症状,但受到副作用和长期疗效降低的限制,对生活质量有显著影响。手术和新的治疗选择提供了更好的运动控制和疗效持久性,尽管它们并非普遍适用。